The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Predicting response to radical (chemo)radiotherapy (R-CRT) with circulating HPV DNA and tumor DNA (ctDNA) analysis in locally-advanced head and neck squamous cell carcinoma (LAHNC).
 
Shreerang Bhide
No Relationships to Disclose
 
Jen Lee
Employment - GlaxoSmithKline (I)
Stock and Other Ownership Interests - GlaxoSmithKline (I)
 
Isaac Garcia-Murillas
No Relationships to Disclose
 
Ros Cutts
No Relationships to Disclose
 
Tara Hurley
No Relationships to Disclose
 
Lorna Grove
No Relationships to Disclose
 
Christopher Nutting
Employment - Advanced Oncotherapy
Leadership - Advanced Oncotherapy
Stock and Other Ownership Interests - Advanced Oncotherapy
Consulting or Advisory Role - Advanced Oncotherapy
Travel, Accommodations, Expenses - MSD
 
Kate Newbold
Honoraria - AstraZeneca; Eisai; Genzyme; SOBI
Consulting or Advisory Role - AstraZeneca; Eisai; Genzyme; SOBI
Speakers' Bureau - AstraZeneca; Eisai
 
Nicholas C. Turner
Consulting or Advisory Role - ADC Therapeutics; AstraZeneca; Novartis; Pfizer; Puma Biotechnology; Roche; SERVIER; Synthon
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); Inivata (Inst); Pfizer (Inst); Roche (Inst)
 
Kevin Harrington
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Merck; MSD; Pfizer
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Merck; MSD; Pfizer
Speakers' Bureau - Amgen; AstraZeneca; Bristol-Myers Squibb; Merck; MSD; Pfizer
Research Funding - Amgen; AstraZeneca; Bristol-Myers Squibb; Merck; MSD; Pfizer